| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
ROCK (Rho-associated kinase), ERK (extracellular signal-regulated kinase), GSK (glycogen synthase kinase), and AGC protein kinases (including PKB/Akt, PKC, PKA). ROCK-IN-5 is a potent inhibitor of these kinases. The multi-kinase inhibition profile makes it useful for studying diverse cellular processes including cytoskeletal dynamics, cell proliferation, survival, and differentiation.
|
|---|---|
| ln Vitro |
ROCK-IN-5 demonstrates potent inhibition of ROCK, ERK, GSK, and AGC kinases in enzymatic assays. The compound shows activity against multiple kinase targets, making it a broad-spectrum tool for kinase research. Detailed IC50 values for individual kinases have not been disclosed in publicly available literature. The compound's multi-target profile distinguishes it from selective kinase inhibitors.
|
| ln Vivo |
In vivo activity of ROCK-IN-5 has not been extensively characterized in published literature. The compound has potential for proliferative, cardiac, and neurodegenerative disease research based on its kinase inhibition profile. In vivo studies would be required to validate its therapeutic potential. Currently, the compound is primarily used as an in vitro research tool.
|
| Enzyme Assay |
In vitro kinase assays are performed using recombinant ROCK, ERK, GSK, or AGC family kinases. The compound (ROCK-IN-5) is incubated with the kinase, ATP, and a substrate peptide. Phosphorylation is detected using radioactivity (³³P-ATP) or fluorescence-based methods (e.g., ADP-Glo, Kinase-Glo, or Transcreener). IC50 values are determined from dose-response curves. Assays are conducted at appropriate ATP concentrations (typically at or below Km).
|
| Cell Assay |
Cells are cultured in appropriate media and treated with ROCK-IN-5 at concentrations typically ranging from 0.1–10 μM for 24–72 hours. Kinase inhibition is assessed by Western blot analysis of downstream phosphorylation targets (e.g., myosin light chain for ROCK, ERK phosphorylation for ERK, GSK-3beta phosphorylation for GSK). Cell proliferation is measured by MTT or CellTiter-Glo assays. Apoptosis is assessed by caspase activation or Annexin V staining.
|
| Animal Protocol |
In vivo animal studies for ROCK-IN-5 have not been reported in publicly available literature. The compound is primarily used for in vitro research. Future studies in animal models of proliferative, cardiac, or neurodegenerative diseases would be needed to evaluate in vivo efficacy. Standard protocols for kinase inhibitor studies in mice or rats could be adapted.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ROCK-IN-5 have not been published. The compound is soluble in DMSO (12.5 mg/mL). It is typically used for in vitro studies. In vivo PK parameters such as half-life, bioavailability, and tissue distribution have not been characterized. For in vivo use, formulation would need to be developed using standard approaches for small-molecule kinase inhibitors.
|
| Toxicity/Toxicokinetics |
Toxicology data for ROCK-IN-5 have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling kinase inhibitors should be observed.
|
| References | |
| Additional Infomation |
ROCK-IN-5 (CAS: 692870-25-0, molecular formula C16H11ClFN3OS, molecular weight 347.79) is a multi-kinase inhibitor. It is referenced in patent WO2004041813A1. The compound is not in clinical trials and has no regulatory approval. It is supplied as a research-grade compound for laboratory use only.
|
| Molecular Formula |
C16H11CLFN3OS
|
|---|---|
| Molecular Weight |
347.79
|
| Exact Mass |
347.029
|
| Elemental Analysis |
C, 55.26; H, 3.19; Cl, 10.19; F, 5.46; N, 12.08; O, 4.60; S, 9.22
|
| CAS # |
692870-25-0
|
| PubChem CID |
4826233
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.662
|
| LogP |
3.11
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
411
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=C(C(=C1)Cl)CC(=O)NC2=NC(=CS2)C3=CC=NC=C3)F
|
| InChi Key |
BPGUVXHQHDKSTA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H11ClFN3OS/c17-12-2-1-3-13(18)11(12)8-15(22)21-16-20-14(9-23-16)10-4-6-19-7-5-10/h1-7,9H,8H2,(H,20,21,22)
|
| Chemical Name |
Benzeneacetamide, 2-chloro-6-fluoro-N-[4-(4-pyridinyl)-2-thiazolyl]-
|
| Synonyms |
WAY-658513; WAY 658513; WAY658513;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8753 mL | 14.3765 mL | 28.7530 mL | |
| 5 mM | 0.5751 mL | 2.8753 mL | 5.7506 mL | |
| 10 mM | 0.2875 mL | 1.4376 mL | 2.8753 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
